Loading...

Brilliant Violet 605™ anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_BV605_CD45_Antibody_FC_080113.jpg
C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 605™ (filled histogram) or rat IgG2b, κ Brilliant Violet 605™ isotype control (open histogram).
  • 30-F11_BV605_CD45_Antibody_FC_080113.jpg
    C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 605™ (filled histogram) or rat IgG2b, κ Brilliant Violet 605™ isotype control (open histogram).
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
103139 125 µL 172€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103155 50 µg 210€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103140 500 µL 348€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining with µg, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For flow cytometric staining with µl, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Wong P, et al. 2021. STAR Protoc. 2:100262. PubMed
  2. Dalmas E et al. 2017. Immunity. 47(5):928-942 . PubMed
  3. Flamar AL, et al. 2020. Immunity. 52(4):606-619.e6.. PubMed
  4. Liang J, et al. 2021. Cancer Manag Res. 13:6977. PubMed
  5. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  6. Zhu Y, et al. 2022. Nat Commun. 13:4282. PubMed
  7. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  8. Krishnamurty AT, et al. 2022. Nature. 611:148. PubMed
  9. Yang H, et al. 2023. Cell Death Differ. 30:560. PubMed
  10. Vyas M, et al. 2023. Front Immunol. 13:1098445. PubMed
  11. Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed
  12. Hettwer J, et al. 2022. Cardiovasc Res. 118:2778. PubMed
  13. Wu MJ, et al. 2022. Cancer Discov. 12:812. PubMed
  14. Michalaki C, et al. 2022. Curr Protoc. 2:e505. PubMed
  15. Zhao L, et al. 2022. Oncogene. 41:4200. PubMed
  16. Roweth HG, et al. 2022. Sci Adv. 8:eabo5224. PubMed
  17. Wang C, et al. 2023. iScience. 26:106272. PubMed
  18. Sambandam A, et al. 2023. Heliyon. 9:e14238. PubMed
  19. Santharam MA, et al. 2023. Int J Mol Sci. 24:. PubMed
  20. De C, et al. 2023. JCI Insight. 8:. PubMed
  21. Liu J, et al. 2023. Nat Commun. 14:2806. PubMed
  22. Mulcrone PL, et al. 2023. Sci Rep. 13:8436. PubMed
  23. Prior JT, et al. 2023. NPJ Vaccines. 8:80. PubMed
  24. Liu X, et al. 2023. J Neuroinflammation. 20:144. PubMed
  25. Israelow B, et al. 2020. bioRxiv. . PubMed
  26. Platt DJ, et al. 2021. Cell Reports. 35(6):109113. PubMed
  27. Boyd DF, et al. 2020. Nature. 587:466. PubMed
  28. Dando SJ, et al. 2021. Invest Ophthalmol Vis Sci. 62:10. PubMed
  29. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  30. Zou C, et al. 2020. Cell Rep. 33:108447. PubMed
  31. Marinaccio C, et al. 2021. Cancer Discovery. 11(6):1398-1410. PubMed
  32. Lee J, et al. 2020. Gut Microbes. 1:. PubMed
  33. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  34. Turner JA, et al. 2020. Immunity. 53:1202. PubMed
  35. Khamissi FZ, et al. 2022. Sci Adv. 8:eabm5900. PubMed
  36. Gao Y, et al. 2020. Nat Cell Biol. 1064:22. PubMed
  37. Shao Y, et al. 2019. Diabetes. 68:2131. PubMed
  38. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  39. Chen JC et al. 2018. Cell systems. 7(1):92-103 . PubMed
  40. Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed
  41. AR P, et al. 2016. Circ Res. 118: 400-409. PubMed
  42. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
  43. Lu SX, et al. 2021. Cell. . PubMed
  44. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  45. Grizotte–Lake M, et al. 2018. Immunity. 49:1103. PubMed
  46. Skibba ME, et al. 2021. Respir Res. 22:315. PubMed
  47. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  48. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  49. Kuhn NF, et al. 2020. Nat Commun. 4.74375. PubMed
  50. Nording H, et al. 2021. Nat Commun. 12:3352. PubMed
  51. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
  52. Payne K, et al. 2016. J Leukoc Biol. 100: 625 - 635. PubMed
  53. Wagner JA, et al. 2020. Cell Rep. 31:107720. PubMed
  54. Freemerman AJ, et al. 2019. J Immunol. 202:1265. PubMed
  55. Celik H, et al. 2021. Cancer Discov. 11:3126. PubMed
  56. Sharma D, et al. 2022. Commun Biol. 5:479. PubMed
  57. Reddy A, et al. 2020. Cell. 183:62. PubMed
  58. Cortez-Toledo O, et al. 2017. PLoS One. 12(2):e0171268. PubMed
  59. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  60. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  61. Ganguly K, et al. 2022. Front Immunol. 13:930449. PubMed
  62. Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed
  63. Harb H, et al. 2021. Immunity. 54(6):1186-1199.e7. PubMed
  64. Gkountela S et al. 2019. Cell. 176(1-2):98-112 . PubMed
  65. Kakizaki M, Watanabe R 2017. Neuropathology. 10.1111/neup.12386. PubMed
  66. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  67. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  68. Baik JE, et al. 2022. Clin Transl Med. 12:e758. PubMed
  69. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  70. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  71. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  72. Chen YG, et al. 2020. Molecular Cell. 76(1):96-109. PubMed
  73. Wolf KG, et al. 2022. JVS Vasc Sci. 3:336. PubMed
  74. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  75. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  76. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  77. Di Mitri D, et al. 2019. Cell Rep. 28:2156. PubMed
  78. Bhattacharya A, et al. 2018. Neuropsychopharmacology. 43:2586. PubMed
  79. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  80. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  81. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  82. Dulken BW, et al. 2019. Nature. 571:205. PubMed
  83. Gyoneva S, et al. 2019. Life Sci Alliance. 2:e201900453. PubMed
  84. Zhang Y, et al. 2019. Nat Commun. 10:3667. PubMed
  85. Myers DR, et al. 2020. Front Immunol. 11:576310. PubMed
  86. Ovadya Y, et al. 2018. Nat Commun. 9:5435. PubMed
  87. Kang YH, et al. 2019. Nat Commun. 10:912. PubMed
  88. McDonald LT, et al. 2017. PLoS One. 12:e0180724. PubMed
  89. Terp MG, et al. 2021. Mol Oncol. 15:3299. PubMed
  90. Harb H, et al. 2020. Nat Immunol. 1359:21. PubMed
  91. Berrien–Elliott MM, et al. 2020. Immunity. 51(3):479-490. PubMed
  92. Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed
  93. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  94. Bennion BG, et al. 2019. J Virol. 93. PubMed
  95. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  96. Pavelko K, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01532. PubMed
  97. Olson CA, et al. 2021. Cell Host Microbe. 29:1378. PubMed
  98. Ren J, et al. 2021. JCI Insight. 6:. PubMed
  99. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  100. Becattini S, et al. 2021. Cell Host Microbe. 29(3):378-393.e5. PubMed
  101. Dai X, et al. 2021. Molecular Cell. 81(11):2317-2331.e6. PubMed
  102. Molgora M, et al. 2020. Cell. 182:886. PubMed
  103. Hong JP, et al. 2020. Cell Reports Medicine. 1(3):100035. PubMed
  104. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  105. Dubrot J, et al. 2021. Immunity. 54(3):571-585.e6. PubMed
  106. Castillo–Azofeifa D, et al. 2019. EMBO J. 38:e99984. PubMed
  107. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  108. Li H, et al. 2022. iScience. 25:104481. PubMed
  109. Perez-Cruz M, et al. 2021. PLoS One. e0236216:16. PubMed
  110. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  111. Lloyd AF, et al. 2019. Nat Neurosci. 1.643055556. PubMed
  112. Shao Y, et al. 2019. Stem Cells. 37:1331. PubMed
  113. Lee A, et al. 2022. Nat Commun. 13:549. PubMed
  114. Avgustinova A, et al. 2021. Cell Stem Cell. . PubMed
  115. Kuhn NF et al. 2019. Cancer cell. 35(3):473-488 . PubMed
RRID
AB_2562341 (BioLegend Cat. No. 103139)
AB_2562341 (BioLegend Cat. No. 103155)
AB_2562341 (BioLegend Cat. No. 103140)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV395™ anti-mouse CD45 30-F11 FC
Go To Top Version: 3    Revision Date: 01.11.2017

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account